4.7 Article

Prognostic Value of Stress Myocardial Perfusion Positron Emission Tomography Results From a Multicenter Observational Registry

期刊

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2012.09.043

关键词

myocardial perfusion imaging; positron emission tomography; prognosis; registry; risk reclassification

资金

  1. Astellas Pharma Global Development
  2. Bracco Diagnostics, Inc
  3. National Heart, Lung, and Blood Institute [K23HL092299]
  4. Heart and Stroke Foundation of Ontario [PRG6242]
  5. Astellas Pharma
  6. Bracco Diagnostics
  7. Toshiba
  8. Lantheus Medical Imaging
  9. GE Healthcare
  10. MDS Nordion
  11. Siemens
  12. Cardium Therapeutics, Inc.

向作者/读者索取更多资源

Objectives The primary objective of this multicenter registry was to study the prognostic value of positron emission tomography (PET) myocardial perfusion imaging (MPI) and the improved classification of risk in a large cohort of patients with suspected or known coronary artery disease (CAD). Background Limited prognostic data are available for MPI with PET. Methods A total of 7,061 patients from 4 centers underwent a clinically indicated rest/stress rubidium-82 PET MPI, with a median follow-up of 2.2 years. The primary outcome of this study was cardiac death (n = 169), and the secondary outcome was all-cause death (n = 570). Net reclassification improvement (NRI) and integrated discrimination analyses were performed. Results Risk-adjusted hazard of cardiac death increased with each 10% myocardium abnormal with mildly, moderately, or severely abnormal stress PET (hazard ratio [HR]: 2.3 [95% CI: 1.4 to 3.8; p = 0.001], HR: 4.2 [95% CI: 2.3 to 7.5; p < 0.001], and HR: 4.9 [95% CI: 2.5 to 9.6; p < 0.0001], respectively [normal MPI: referent]). Addition of percent myocardium ischemic and percent myocardium scarred to clinical information (age, female sex, body mass index, history of hypertension, diabetes, dyslipidemia, smoking, angina, beta-blocker use, prior revascularization, and resting heart rate) improved the model performance (C-statistic 0.805 [95% CI: 0.772 to 0.838] to 0.839 [95% CI: 0.809 to 0.869]) and risk reclassification for cardiac death (NRI 0.116 [95% CI: 0.021 to 0.210]), with smaller improvements in risk assessment for all-cause death. Conclusions In patients with known or suspected CAD, the extent and severity of ischemia and scar on PET MPI provided powerful and incremental risk estimates of cardiac death and all-cause death compared with traditional coronary risk factors. (J Am Coll Cardiol 2013; 61: 176-84) (C) 2013 by the American College of Cardiology Foundation

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据